The genetics of neuroendocrine tumors

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 37-44

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; DAXX PROTEIN; EVEROLIMUS; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN P53; PROTEIN RET; SMAD3 PROTEIN; SMAD4 PROTEIN; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CARCINOGENESIS; CARNEY COMPLEX; CHROMOSOME 11Q; CHROMOSOME 16Q; CHROMOSOME 9P; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LUNG TUMOR; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; PARAGANGLIOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMALL INTESTINE TUMOR; SOMATIC MUTATION; TUBERCULOSIS; VON HIPPEL LINDAU DISEASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; DNA HELICASES; HUMANS; INDOLES; MUTATION; NEUROENDOCRINE TUMORS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PYRROLES; SIROLIMUS;

EID: 84873363364     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.005     Document Type: Article

References (103)

1. D. Hanahan, R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2001 646 674
2. A. Calender Genetics of neuroendocrine tumours L. Kvolls, M. Caplin, Handbook of neuroendocrine tumours: their current and future management 2006 Bioscientifica Bristol 53 79
3. The European Consortium of MEN-1 Identification of the multiple endocrine neoplasia type 1 (MEN-1) gene Hum Mol Genet 6 1997 1177 1183
4. S. Marx, A.M. Spiegel, M.C. Skarulis, J.L. Doppman, F.S. Collins, L.A. Liotta Multiple endocrine neoplasia type 1: clinical and genetic topics Ann Intern Med 129 1998 484 494
5. C. Larsson, B. Skogseid, K. Oberg, Y. Nakamura, M. Nordenskjold Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma Nature 332 1988 85 87
6. S.C. Chandrasekharappa, S.C. Guru, P. Manickam Positional cloning of the gene for multiple endocrine neoplasia-type 1 Science 276 1997 404 407
7. M.R. Emmert-Buck, I.A. Lubensky, Q. Dong Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis Cancer Res 57 1997 1855 1858
8. I. Lemmens, W.J. Van de Ven, K. Kas Identification of the multiple endocrine neoplasia type 1 (MEN1) gene The European Consortium on MEN1 Hum Mol Genet 6 1997 1177 1183
9. E.H. Wang, S.A. Ebrahimi, A.Y. Wu, C. Kashefi, E. Passaro Jr, M.P. Sawicki Mutation of the MENIN gene in sporadic pancreatic endocrine tumors Cancer Res 58 1998 4417 4420
10. Z. Zhuang, A.O. Vortmeyer, S. Pack Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas Cancer Res 57 1997 4682 4686
11. L.V. Debelenko, E. Brambilla, S.K. Agarwal Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung Hum Mol Genet 6 1997 2285 2290
12. T.R. Prezant, J. Levine, S. Melmed Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors J Clin Endocrinol Metab 83 1998 1388 1391
13. H. Tahara, Y. Imanishi, T. Yamada Rare somatic inactivation of the multiple endocrine neoplasia type 1 gene in secondary hyperparathyroidism of uremia J Clin Endocrinol Metab 85 2000 4113 4117
14. S.C. Guru, S.E. Olufemi, P. Manickam A 2.8-Mb clone contig of the multiple endocrine neoplasia type 1 (MEN1) region at 11q13 Genomics 42 1997 436 445
15. S.C. Guru, P.K. Goldsmith, A.L. Burns Menin, the product of the MEN1 gene, is a nuclear protein Proc Natl Acad Sci U S A 95 1998 1630 1634
16. S.K. Agarwal, S.C. Guru, C. Heppner Menin interacts with the AP1 transcription factor JunD and represses JunD-Activated transcription Cell 96 1999 143 152
17. A.E. Gobl, M. Berg, J.R. Lopez-Egido, K. Oberg, B. Skogseid, G. Westin Menin represses JunD-Activated transcription by a histone deacetylase-dependent mechanism Biochim Biophys Acta 1447 1999 51 56
18. S.K. Agarwal, P.C. Scacheri, T.S. Rice MEN1 gene: mutation and pathophysiology Ann Endocrinol 67 Suppl 4 2006 IS12 IS13
19. D. Thepot, J.B. Weitzman, J. Barra Targeted disruption of the murine junD gene results in multiple defects in male reproductive function Development 127 2000 143 153
20. S.K. Karnik, C.M. Hughes, X. Gu Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c Proc Natl Acad Sci U S A 102 2005 14659 14664
21. T. Carling, P. Correa, O. Hessman Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism J Clin Endocrinol Metab 83 1998 2960 2963
22. O. Hessman, D. Lindberg, B. Skogseid Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas Cancer Res 58 1998 377 379
23. O. Hessman, B. Skogseid, G. Westin, G. Akerstrom Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors J Clin Endocrinol Metab 86 2001 1355 1361
24. Y. Jiao, C. Shi, B.H. Edil DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
25. F. Raue, K. Frank-Raue Update multiple endocrine neoplasia type 2 Fam Cancer 9 2010 449 457
26. S. Leboulleux, J.P. Travagli, B. Caillou Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course Cancer 94 2002 44 50
27. M. Takahashi, J. Ritz, G.M. Cooper Activation of a novel human transforming gene, ret, by DNA rearrangement Cell 42 1985 581 588
28. I. Schuffenecker, N. Ginet, D. Goldgar Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma Le Groupe d'Etude des Tumeurs a Calcitonine Am J Hum Genet 60 1997 233 237
29. H. Donis-Keller, S. Dou, D. Chi Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 2 1993 851 856
30. L.M. Mulligan, J.B. Kwok, C.S. Healey Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 1993 458 460
31. P. Durbec, C.V. Marcos-Gutierrez, C. Kilkenny GDNF signalling through the Ret receptor tyrosine kinase Nature 381 1996 789 793
32. S. Jing, D. Wen, Y. Yu GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-Alpha, a novel receptor for GDNF Cell 85 1996 1113 1124
33. M. Trupp, E. Arenas, M. Fainzilber Functional receptor for GDNF encoded by the c-ret proto-oncogene Nature 381 1996 785 789
34. J.J. Treanor, L. Goodman, F. de Sauvage Characterization of a multicomponent receptor for GDNF Nature 382 1996 80 83
35. V. Besset, R.P. Scott, C.F. Ibanez Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase J Biol Chem 275 2000 39159 39166
36. D. Califano, C. Rizzo, A. D'Alessio Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells J Biol Chem 275 2000 19297 19305
37. C. Segouffin-Cariou, M. Billaud Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway J Biol Chem 275 2000 3568 3576
38. R.M. Hofstra, R.M. Landsvater, I. Ceccherini A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma Nature 367 1994 375 376
39. P. Edery, S. Lyonnet, L.M. Mulligan Mutations of the RET proto-oncogene in Hirschsprung's disease Nature 367 1994 378 380
40. C. Eng, D. Clayton, I. Schuffenecker The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 International RET mutation consortium analysis JAMA 276 1996 1575 1579
41. L.M. Mulligan, C. Eng, C.S. Healey Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC Nat Genet 6 1994 70 74
42. M.A. Kouvaraki, S.E. Shapiro, N.D. Perrier RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors Thyroid 15 2005 531 544
43. T. Iwashita, N. Asai, H. Murakami, M. Matsuyama, M. Takahashi Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation Oncogene 12 1996 481 487
44. A. Miyauchi, H. Futami, N. Hai Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation Jpn J Cancer Res 90 1999 1 5
45. D. Erickson, Y.C. Kudva, M.J. Ebersold Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients J Clin Endocrinol Metab 86 2001 5210 5216
46. R. DeLellis, R. Lloyd, P.U. Heitz, C. Eng World Health Organisation classification of tumors Pathology and genetics: tumor of endocrine organs 2004 IARC Press Lyon 147 166
47. J. Rutter, D.R. Winge, J.D. Schiffman Succinate dehydrogenase - assembly, regulation and role in human disease Mitochondrion 10 2010 393 401
48. B.E. Baysal, R.E. Ferrell, J.E. Willett-Brozick Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 287 2000 848 851
49. N. Burnichon, V. Rohmer, L. Amar The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas J Clin Endocrinol Metab 94 2009 2817 2827
50. A.P. Gimenez-Roqueplo, J. Favier, P. Rustin The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway Am J Hum Genet 69 2001 1186 1197
51. P.B. Douwes Dekker, P.C. Hogendoorn, N. Kuipers-Dijkshoorn SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology J Pathol 201 2003 480 486
52. A.J. Gill, D.E. Benn, A. Chou Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes Hum Pathol 41 2010 805 814
53. E. Korpershoek, J. Favier, J. Gaal SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas J Clin Endocrinol Metab 96 2011 E1472 E1476
54. D. Astuti, F. Douglas, T.W. Lennard Germline SDHD mutation in familial phaeochromocytoma Lancet 357 2001 1181 1182
55. D. Astuti, F. Latif, A. Dallol Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma Am J Hum Genet 69 2001 49 54
56. F. Schiavi, C.C. Boedeker, B. Bausch Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene JAMA 294 2005 2057 2063
57. H.X. Hao, O. Khalimonchuk, M. Schraders SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma Science 325 2009 1139 1142
58. H.P. Neumann, C. Pawlu, M. Peczkowska Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations JAMA 292 2004 943 951
59. A.P. Gimenez-Roqueplo, J. Favier, P. Rustin Mutations in the SDHB gene are associated with extra-Adrenal and/or malignant phaeochromocytomas Cancer Res 63 2003 5615 5621
60. N. Burnichon, J.J. Briere, R. Libe SDHA is a tumor suppressor gene causing paraganglioma Hum Mol Genet 19 2010 3011 3020
61. C.A. Stratakis, J.A. Carney The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications J Intern Med 266 2009 43 52
62. E.R. Woodward, E.R. Maher Von Hippel-Lindau disease and endocrine tumour susceptibility Endocr Relat Cancer 13 2006 415 425
63. S. Richard, C. Beigelman, J.M. Duclos Pheochromocytoma as the first manifestation of von Hippel-Lindau disease Surgery 116 1994 1076 1081
64. M. Baghai, G.B. Thompson, W.F. Young Jr, C.S. Grant, V.V. Michels, J.A. van Heerden Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery Arch Surg 137 2002 682 688
65. M.M. Walther, R. Reiter, H.R. Keiser Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma J Urol 162 1999 659 664
66. F. Latif, K. Tory, J. Gnarra Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320
67. F.M. Richards, P.N. Schofield, S. Fleming, E.R. Maher Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis Hum Mol Genet 5 1996 639 644
68. W.G. Kaelin Jr The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer Nat Rev Cancer 8 2008 865 873
69. S.T. Lott, D.S. Chandler, S.A. Curley High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-Associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis Cancer Res 62 2002 1952 1955
70. R.R. Lonser, G.M. Glenn, M. Walther von Hippel-Lindau disease Lancet 361 2003 2059 2067
71. K.P. Boyd, B.R. Korf, A. Theos Neurofibromatosis type 1 J Am Acad Dermatol 61 2009 1 14
72. H. Kehrer-Sawatzki, D.N. Cooper Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? J Med Genet 45 2008 622 631
73. M.M. Walther, J. Herring, E. Enquist, H.R. Keiser, W.M. Linehan von Recklinghausen's disease and pheochromocytomas J Urol 162 1999 1582 1586
74. C.M. Johannessen, E.E. Reczek, M.F. James, H. Brems, E. Legius, K. Cichowski The NF1 tumor suppressor critically regulates TSC2 and mTOR Proc Natl Acad Sci U S A 102 2005 8573 8578
75. C.M. Johannessen, B.W. Johnson, S.M. Williams TORC1 is essential for NF1-Associated malignancies Curr Biol 18 2008 56 62
76. E. Missiaglia, I. Dalai, S. Barbi Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 2010 245 255
77. L. Rachdi, N. Balcazar, F. Osorio-Duque Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner Proc Natl Acad Sci U S A 105 2008 9250 9255
78. O. Hessman, D. Lindberg, A. Einarsson Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-Associated pancreatic endocrine tumors Genes Chromosomes Cancer 26 1999 258 264
79. D. Lindberg, G. Akerstrom, G. Westin Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours Clin Endocrinol (Oxf) 66 2007 110 114
80. A.J. Levine, W. Hu, Z. Feng The P53 pathway: what questions remain to be explored? Cell Death Differ 13 2006 1027 1036
81. W. Hu, Z. Feng, I. Modica Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway Genes Cancer 1 2010 360 368
82. D.E. Hansel, A. Rahman, M. House Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms Clin Cancer Res 10 2004 6152 6158
83. E.M. Duerr, Y. Mizukami, A. Ng Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis Endocr Relat Cancer 15 2008 243 256
84. K. Hemminki, X. Li Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden Int J Cancer 94 2001 444 448
85. S. Kytola, A. Hoog, B. Nord Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids Am J Pathol 158 2001 1803 1808
86. R.M. Lollgen, O. Hessman, E. Szabo, G. Westin, G. Akerstrom Chromosome 18 deletions are common events in classical midgut carcinoid tumors Int J Cancer 92 2001 812 815
87. G.G. Wang, J.C. Yao, S. Worah Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors Mod Pathol 18 2005 1079 1087
88. M.H. Kulke, E. Freed, D.Y. Chiang High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss Genes Chromosomes Cancer 47 2008 591 603
89. E. Andersson, C. Sward, G. Stenman, H. Ahlman, O. Nilsson High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids Endocr Relat Cancer 16 2009 953 966
90. J.L. Cunningham, T. Diaz de Stahl, T. Sjoblom, G. Westin, J.P. Dumanski, E.T. Janson Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors Genes Chromosomes Cancer 50 2011 82 94
91. W.D. Travis Lung tumours with neuroendocrine differentiation Eur J Cancer 45 Suppl 1 2009 251 266
92. B.I. Gustafsson, M. Kidd, A. Chan, M.V. Malfertheiner, I.M. Modlin Bronchopulmonary neuroendocrine tumors Cancer 113 2008 5 21
93. W.D. Travis Advances in neuroendocrine lung tumors Ann Oncol 21 Suppl 7 2010 vii65 vii71
94. L. Righi, M. Volante, I. Rapa, G.V. Scagliotti, M. Papotti Neuro-endocrine tumours of the lung A review of relevant pathological and molecular data Virchows Arch 451 Suppl 1 2007 S51 S59
95. P.D. Leotlela, A. Jauch, H. Holtgreve-Grez, R.V. Thakker Genetics of neuroendocrine and carcinoid tumours Endocr Relat Cancer 10 2003 437 450
96. J. Zhao, R.R. de Krijger, D. Meier Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis Am J Pathol 157 2000 1431 1438
97. S. Petzmann, R. Ullmann, I. Halbwedl, H.H. Popper Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study Virchows Arch 445 2004 151 159
98. A.K. Walch, H.F. Zitzelsberger, M.M. Aubele Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization Am J Pathol 153 1998 1089 1098
99. Wistuba II, C. Behrens, A.K. Virmani High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints Cancer Res 60 2000 1949 1960
100. D.R. Swarts, M. Henfling, F.C. Ramaekers Reduced MEN1 gene expression in pulmonary carcinoids is associated with metastatic disease Neuroendocrinology 94 2011 12
101. N. Haruki, Y. Yatabe, W.D. Travis Characterization of high-grade neuroendocrine tumors of the lung in relation to menin mutations Jpn J Cancer Res 91 2000 317 323
102. R.M. Przygodzki, S.D. Finkelstein, J.C. Langer Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors Correlation with histological subtype and clinical outcome Am J Pathol 148 1996 1531 1541
103. E. Brambilla, S. Gazzeri, S. Lantuejoul p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer Clin Cancer Res 4 1998 1609 1618